Search
Polatuzumab Vedotin (POLIVY)
Indications:
- component of rituximab, cyclophosphamide, doxorubicin, Polatuzumab Vedotin, & prednisone (pola-R-CHP) used for treatment of previously untreated intermediate- risk or high-risk diffuse large B-cell lymphoma (DLBCL) [1]
- indicated in combination with bendamustine & a rituximab product for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, after at least two prior therapies [2]
Dosage:
- 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles in combination with bendamustine & a rituximab product
- subsequent infusions may beadministered over 30 minutes if the previous infusion is tolerated
- six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone
* Premedicate with an antihistamine & antipyretic
Injection: 30 mg or 140 mg of polatuzumab vedotin-piiq as a lyophilized powder in a single-dose vial.
Adverse effects:
- peripheral neuropathy
- myelosuppression
- progressive multifocal leukoencephalopathy
- hepatotoxicity
- tumor lysis syndrome
Mechanism of action:
- antibody-drug conjugate targeting CD79b, ubiquitously expressed on surface of malignant B cells
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
Related
diffuse large B-cell lymphoma (DLBCL)
General
antineoplastic agent (chemotherapeutic agent)
pharmaceutical monoclonal antibody
References
- Tilly H, Morschhauser F, Sehnv LH et al
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med 2021. December 14.
PMID: 34904799
https://www.nejm.org/doi/full/10.1056/NEJMoa2115304
- Highlights of prescribing information
https://www.gene.com/download/pdf/polivy_prescribing.pdf